More than ten years ago the dipeptidyl boronic acid derivative proteasome inhibitor bortezomib changed the therapeutic field of multiple myeloma dramatically. This introduction of a whole new class of chemotherapy lead to a significant extension of disease-free and overall survival for most myeloma patients. But as with most first-in-class molecules, efficacy can probably be improved — primary and secondary bortezomib resistance being common – and treatment is all too often limited by dose-limiting side effects.2 Carfilzomib is without doubt a very promising next generation proteasome inhibitor.

(BELG J HEMATOL 2015;6(2):71–3)